Harmony Biosciences to Participate in 24th Annual Needham Virtual Healthcare Conference

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the upcoming 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025, at 3:00 p.m. ET.

A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/.

About Harmony Biosciences

Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa, we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250326602540/en/

Harmony Biosciences Investor Contact:
Brennan Doyle
484-539-9700
[email protected]

Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
[email protected]

Source: Harmony Biosciences Holdings, Inc.

You May Also Be Interested In

• ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer
• ErieView Development Closes $218 Million in Financing for W Cleveland at Erieview Tower
• Forge Resources Advances La Estrella as Coal Prices Hold Strong and Colombia's New Government Reopens the Resource Sector